MacroGenics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MacroGenics and other ETFs, options, and stocks.

About MGNX

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases.

CEO

Scott E. Koenig

CEOScott E. Koenig

Employees

341

Employees341

Headquarters

Rockville, Maryland

HeadquartersRockville, Maryland

Founded

2000

Founded2000

Employees

341

Employees341

MGNX Key Statistics

Market cap

93.37M

Market cap93.37M

Price-Earnings ratio

-1.67

Price-Earnings ratio-1.67

Dividend yield

—

Dividend yield—

Average volume

334.43K

Average volume334.43K

High today

$1.58

High today$1.58

Low today

$1.47

Low today$1.47

Open price

$1.54

Open price$1.54

Volume

264.59K

Volume264.59K

52 Week high

$5.77

52 Week high$5.77

52 Week low

$0.9897

52 Week low$0.9897

MGNX News

Simply Wall St 7d

Analyst Forecasts For MacroGenics, Inc. Are Surging Higher

MacroGenics, Inc. ( ) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. The consensus stat...

Analyst ratings

71%

of 7 ratings

Buy

28.6%

Hold

71.4%

Sell

People also own

Based on the portfolios of people who own MGNX. This list is generated using Robinhood data, and it’s not a recommendation.